Quantitative benefit-risk analysis for evaluating drug therapies

Journal of Biopharmaceutical Statistics

Volumn 23, Issue 1, 2013, Pages 231-238

  Kodell, Ralph L ^a   Chen, James J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Adverse event; AUC; Drug withdrawal; ROC curve; Sensitive subpopulation

Indexed keywords

NEW DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; HUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; ROC CURVE; TREATMENT OUTCOME;

EID: 84873284949     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2013.735785     Document Type: Article

References (16)

1. Andrews, J. R. (1985). Benefit, risk, and optimization by ROC analysis in cancer radiotherapy. International Journal Radiation Oncology-Biology-Physics 11:1557-1562. (Pubitemid 15033584)
2. Congressional Budget Office, Congress of the United States. (2007). Research on the Comparative Effectiveness of Medical Treatments. Pub. no. 2975. Washington, DC: Congressional Budget Office, December.
3. Delongchamp, R. R., Bowyer, J. F., Chen, J. J., Kodell, R. L. (2004). Multiple-testing strategy for analyzing cDNA array data on gene expression. Biometrics 60:774-782. (Pubitemid 39181123)
4. Donaldson, C., Baker, R., Mason, H., Jones-Lee, M., Lancsar, E., Wildman, J., Bateman, I., Loomes, G., Robinson, A., Sugden, R., Pinto Prades, J. L., Ryan, M., Shackley, P., Smith, R. (2011). The social value of a QALY: Raising the bar or barring the raise? BMC Health Services Research 11:8.
5. Entsuah, R., Gao, B. (2002). Global benefit-risk evaluation of antidepressant action: Comparison of pooled data for Venlafaxine, SRRIs and placebo. CNS Spectrums 7:882-888. (Pubitemid 36765048)
6. Food and Drug Administration. (2011). Draft Guidance for Industry and Food and Drug Administration Staff, Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Review. August 15. Available at www.fda.gov/MedicalDevices/DeviceReglationandGuidance/GuidanceDocuments/ ucm267829.htm
7. Garrison, L. P., Jr., Towse, A., Bresnahan, B. W. (2007). Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Affairs 26:684-695.
8. Holden W. L., Juhaeri, J., Dai, W. (2003). Benefit-risk analysis: A proposal using quantitative methods. Pharmacoepidemiology and Drug Safety 12:611-616. (Pubitemid 37220648)
9. Kodell, R. L., Chen, J. J. (2010) Is premarket identification of hepatotoxic drugs and sensitive patients possible based on high-dimensional 'omic data? Personalized Medicine 7:171-178.
10. Moore, D. H., Mendelsohn, M. L. (1972). Optimal treatment levels in cancer therapy. Cancer 30:97-106.
11. National Institute for Health and Clinical Excellence. (2011). Guide to the Methods of Technology Appraisal. Available at www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf (accessed September 21, 2011).
12. O'Neill, R. T. (2008). A perspective on characterizing benefits and risks derived from clinical trials: Can we do more? Drug Information Journal 42:235-245. (Pubitemid 351775942)
13. Phillips, C. (2009). What is a QALY? Hayward Medical Communications. Available at www. whatisseries.co.uk (accessed September 21, 2011).
14. Shaffer, M. L., Watterberg, K. L. (2006). Joint distribution approaches to simultaneously quantifying benefit and risk. BMC Medical Research Methodology 6:48.
15. Shukovsky, L. J., Baeza, M. R., Fletcher, G. H. (1976). Results of irradiation in squamous cell carcinomas of the glossopalatine sulcus. Radiology 120:405-408.
16. Zweig, M. H., Campbell, G. (1993). Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clinical Chemistry 39:561-577. (Pubitemid 23118304)